Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

LIF and sLIFr alterations during reconvalescence (novel coronavirus infection, influenza) in patients with essential hypertension

About authors

1 National Research Mordovia State University, Saransk, Russia

2 State Research and Development Institute of High Purity Biologicals of the Federal Medical and Biological Agency, Saint-Petersburg, Russia

Correspondence should be addressed: Olga A. Radaeva
Ulyanov, 26а, Saransk, 430032, Russia; ur.liam@demaveadar

About paper

Funding: the study was supported by the RSF grant “Analysis of changes in circadian rhythms of cytokine synthesis in the blood of patients with essential arterial hypertension as a predictor of the development of cardiovascular complications”, No. 23-25-00147.

Author contribution: Radaeva OA — developing the study design, analysis of the results, manuscript formatting; Simbirtsev AS — phrasing of the aim of the study, manuscript editing; Kostina YuA — laboratory testing, manuscript formatting; Iskandyarova MS — literature review, manuscript editing; Negodnova EV — literature review, patient follow-up; Solodovnikova GA — statistical data processing; Eremeev VV — manuscript editing; Krasnoglazova KA, Babushkin IO — statistical processing of the 6-month follow-up data.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Ogarev Mordovia State University (protocol No. 12 dated 14 December 2008, additional protocol No. 85 dated 27 May 2020). The informed consent was submitted by all patients. Biomaterial (blood) was collected for further testing considering provisions of the WMA Declaration of Helsinki (2013) and the protocol of the Convention on Human Rights and Biomedicine developed by the Council of Europe (1999) considering supplementary protocol of the Convention on Human Rights and Biomedicine in the field of biomedical research (2005).

Received: 2024-11-28 Accepted: 2025-02-18 Published online: 2025-02-26
|

Today, the analysis of the risk of developing cardiovascular complications in patients with essential hypertension (EH) following recovery from novel coronavirus infection (COVID-19) is relevant. The value of leukemia inhibitory factor (LIF) and its soluble receptor (sLIFr) in EH progression has been shown, along with the relevance of circadian approaches to assessment of the contribution of pro-inflammatory cytokines to the pathogenesis of acute cerebrovascular accidents (CVA). The study aimed to compare alterations of the LIF and sLIFr levels during reconvalescence after COVID-19 and influenza in patients with stage II EH, to determine the features that are important for the development of acute CVA, and to analyze the associations with circadian rhythms. The study was conducted in four phases (n = 180; age 55–60 years): (1) 6–8 months before COVID-19; (2–3) on day 10–14 after primary or recurrent COVID-19; (4) on day 10–14 after influenza. In each phase blood levels of LIF and sLIFr were determined by enzyme immunoassay at 7.00–8.00 h and 19.00–20.00 h, in 12 patients in four phases — at 7.00–8.00 h, 12.00–13.00 h, 19.00–20.00 h, 23.00–1.00 h throughout three days. It has been demonstrated that patients with EH show elevated LIF and sLIFr levels relative to healthy individuals in all time points (р ˂ 0.001) and significantly elevated levels at 19.00–20.00 h (р ˂ 0.001). The analysis of the relationship between circadian rhythms and blood levels of LIF, sLIFr in patients with stage II EH post COVID-19 and influenza has revealed similar changes in the form of the larger increase in sLIFr levels at 19.00–20.00 h (the ROC analysis data has shown predictive value for developing acute CVA within a year after СOVID-19 in cases of the value increase above 7100 pg/L at 19.00–20.00 h). The principles revealed actualize further investigation of the effects of the LIF/sLIFr complex associated with the EH progression after acute infectious diseases.

КОММЕНТАРИИ (0)